High Growth Tech Stocks To Watch In The US March 2025

In This Article:

Over the last 7 days, the United States market has experienced a 4.6% drop, yet it remains up by 8.8% over the past year with earnings projected to grow by 14% annually. In this context of fluctuating performance and promising growth forecasts, identifying high-growth tech stocks involves focusing on companies with strong innovation potential and robust financial health that can capitalize on these market conditions.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

TG Therapeutics

26.19%

37.78%

★★★★★★

Alkami Technology

21.98%

85.17%

★★★★★★

Travere Therapeutics

28.43%

65.01%

★★★★★★

Alnylam Pharmaceuticals

22.90%

58.64%

★★★★★★

AVITA Medical

27.78%

55.33%

★★★★★★

Bitdeer Technologies Group

44.71%

127.60%

★★★★★★

Clene

61.16%

59.11%

★★★★★★

Blueprint Medicines

22.38%

55.75%

★★★★★★

Alvotech

31.17%

100.18%

★★★★★★

Lumentum Holdings

21.24%

119.37%

★★★★★★

Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

Aldeyra Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing and commercializing medicines for immune-mediated diseases, with a market cap of $379.15 million.

Operations: Aldeyra Therapeutics focuses on developing and commercializing treatments for immune-mediated diseases. The company operates within the biotechnology sector, with a market capitalization of approximately $379.15 million.

Aldeyra Therapeutics, despite its current unprofitability and minimal revenue under $1 million, is positioned for significant growth with expected annual revenue increases of 41.4% and earnings growth forecasted at 55.5%. This ambitious growth trajectory outpaces the general US market's average of 8.4% and aligns with projections that see the company turning profitable within three years. Recent strategic movements include a new shelf registration aimed at bolstering financial flexibility and presentations at major healthcare conferences, signaling active engagement in expanding its market presence and investor relations. These steps could catalyze Aldeyra’s transition from a high-potential firm to a profitable entity in the burgeoning biotech sector.

NasdaqCM:ALDX Earnings and Revenue Growth as at Mar 2025
NasdaqCM:ALDX Earnings and Revenue Growth as at Mar 2025

Blackbaud

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Blackbaud, Inc. provides cloud software and services both in the United States and internationally, with a market capitalization of approximately $3.18 billion.